Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed...
Dessight Biomedical
Dessight Biomedical Secures RMB 100M Series A Funding for Surgical Robot Development
Hangzhou-based Dessight Biomedical, a provider of ultra-microsurgery precision solutions, has completed a Series A funding...
Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A...